Good morning. Thanks for joining us for another session at the 43rd JP Morgan Healthcare Conference. I'm Brian Cheng, one of the Senior Biotech Analysts here at the firm. I'm joined by my associate, Seong Kim, and Marianne Wangari, who are also in the audience. On stage, we have the team from Blueprint Medicines. I will now pass the mic to their CEO, Kate Haviland, for a short presentation followed by a live audience Q&A. Kate, the stage is yours. Thank you very much, Brian, for that introduction, and I want to thank the entire JPMorgan Healthcare team for inviting us to present today. It's nice to see people here in the room, and I also welcome everyone who is joining us on the webcast. My name is Kate Haviland, as Brian just mentioned. I'm the President and CEO of Blueprint Medicines, and this is actually my 10th JPMorgan meeting with Blueprint, so kind of a milestone. Very happy to be here with you all. In the audience are a number of my executive leaders, but up here on the stage, I have Christy Rossi, who is our Chief Operating Officer, and Fouad Namouni, our President of Research and Development, who will be joining me for the Q&A portion of the presentation, and so Blueprint Medicines is a company that is focused on driving growth and innovation with operational excellence. I am very pleased to be here to represent the exceptional progress our entire Blueprint Medicines team has made in 2024 and to lay out all the exciting milestones we have in front of us here in 2025 as we work to continue to deliver substantial near-term and longer-term value for both patients and shareholders. So during the presentation today, I'll be making forward-looking statements. And I ask you to refer to our SEC filings for risk factors. So many of you know Blueprint and have followed us for years. But some of you are new to the story. And for those of you who are newer to the story, this slide really is a snapshot encapsulating who we are. At Blueprint Medicines, our aspiration is to fundamentally change the way allergic inflammatory diseases are treated by targeting the mast cell. Over the past number of years, there's been a growing appreciation of the role of mast cells in the pathophysiology of a range of allergic inflammatory diseases. And we at Blueprint Medicines are uniquely positioned to drive innovation in this space because of our long history pioneering in this area of science. From the earliest days of the company's founding, we have been working on modulating mast cell biology by targeting KIT, which is really the master control switch on the mast cell. That work has resulted in our approved medicine, AYVAKIT. AYVAKIT is approved for the treatment of patients with a rare disease with high medical need called Systemic Mastocytosis, or SM. AYVAKIT's deep and sustained symptom impact and very well-tolerated safety profile has transformed the treatment of this disease. And the SM market is bigger than we thought and is growing faster than we expected. We now estimate that the Blueprint SM franchise will reach a peak of $4 billion, with AYVAKIT as the anchor reaching $2 billion by 2030. This is an incredible and outstanding opportunity. Given the scale of this opportunity, we are taking a thoughtful approach to maximizing the life cycle of this franchise over the long-term with our next generation D816V inhibitor, elenestinib, which we'll talk more about today. We are also taking advantage of being a fully integrated company. We now are able to align insights and create almost a flywheel of innovation between research, development, and now our commercial team, which has resulted in operating leverage and scalable innovation. This dynamic is exemplified by our BLU-808 program targeting wild-type KIT. The motivation for this program grew out of our interactions with a broad range of healthcare providers in the Allergy Immunology space who are treating Systemic Mastocytosis patients. As we would be talking to them about SM, we would hear about the profound need they see for new treatments for many of their other patients beyond SM and the idea that targeting mast cells could be really impactful for those patients as well. Our talented research scientists delivered BLU-808 and later in my presentation, I will talk about our unique and differentiated approach that we are taking to modulating mast cell biology with wild-type KIT by targeting wild-type KIT with BLU-808. We believe our differentiated approach is going to allow us to unlock the true pipeline and medicine potential that BLU-808 represents. I'm also very pleased, for the first time today, to be able to present data on the clinical profile of BLU-808 with our top-line data coming out of our phase I healthy volunteer study. But before focusing on 2025, I want to take a moment to reflect on the strong execution we had across the board in 2024. We reached a $500 million run rate with AYVAKIT, fueled by our ongoing launch in Indolent Systemic Mastocytosis, or ISM. This places AYVAKIT firmly on the path to realizing the multi-billion-dollar peak revenue opportunity and positions AYVAKIT's launch in ISM to be one of the most successful rare disease launches to date. We expect to deliver 130% year-over-year growth in revenue by significantly increasing the number of SM patients who are on therapy and by starting to see the cumulative effects of keeping those patients on therapy for long durations. Our international team also delivered strong revenue growth results in 2024 through their ISM launch in Germany and also continuing to broaden and expand the access to AYVAKIT across numerous countries for advanced SM. We made progress on our longer-term SM life cycle strategy by initiating the phase III study of elenestinib in ISM. We filed the IND for BLU-808 in the middle of the year and efficiently executed the phase I healthy volunteer study in less than six months, enabling us to present data today. And we did all of this while maintaining financial discipline. We are anticipating a significant reduction in our cash burn in 2024, maintaining a strong and durable financial position for the company going forward. So due to this tremendous operational excellence of the entire Blueprint Medicines team, we are entering 2025 in the strongest position we have ever been as a company. Our areas of focus to create value this year include continuing to drive AYVAKIT revenue growth, building the SM franchise for the long-term with elenestinib, defining the broad potential of BLU-808 as our next blockbuster opportunity, and advancing our earliest stage portfolio. I'm going to touch on each one of these topics today. But before we dive into the details, I want to highlight that our 2025 capital allocation strategy is aligned with our plan for value creation. 80% of our planned 2025 OpEx will be allocated to the three core value drivers you see here on the slide on the left: AYVAKIT revenue growth, elenestinib, and BLU-808. 20% of our capital will be allocated to advancing our portfolio of earlier stage programs that will be the core value drivers of tomorrow for Blueprint Medicines. This capital allocation enables us to drive significant near-term growth while solidifying ourselves as leaders in the mast cell space for the long-term. It also leverages our commercial scale and our deep scientific expertise to drive innovation with financial efficiency. So turning to AYVAKIT. AYVAKIT is a medicine that is changing patients' lives. We hear from patients regularly about how treatment with AYVAKIT has allowed them to reclaim control of their lives and how after starting treatment, they realize how much they had accommodated their disease by limiting their lives, by making their impact, their ability to work, their ability to socialize, their ability to participate in family events so much smaller than they had even recognized themselves. Pictured here is one of our patients, Andrew. He is a patient with ISM. And before AYVAKIT, he and his provider treated numerous symptoms. He had fatigue. He had itchy and terrible skin rashes, GI issues, bone pain, and with common symptomatic directed therapies, which he referred to as cumbersome palliative care. He did not see the benefit he wanted. He described this as a game of whack-a-mole because his symptoms were severe. They were unpredictable. They were constantly changing, and none of the symptomatic medicines he was taking gave him adequate relief or control over the disease. In 2023, Andrew began taking AYVAKIT, and his symptoms have improved dramatically, enabling him to control his ISM with confidence and to live his life more freely. With transformational impacts such as what Andrew has experienced, AYVAKIT is quickly becoming the standard of care across both Advanced Systemic Mastocytosis and Indolent Systemic Mastocytosis. When building a new rare disease market, we know that the introduction of a highly effective medicine has been the catalyst for market growth for many other important medicines, and we are seeing that exact same dynamic play out here in Systemic Mastocytosis, driven by the introduction of AYVAKIT, the first medicine specifically designed to stop ISM at its source. As I mentioned before, we always believe the SM market was a sizable and scaled rare disease market, but it is bigger than we thought, and it's growing faster than we expected. We have raised the awareness and clinical suspicion of SM through our broad educational efforts, and you pair that raised awareness with the availability of AYVAKIT, a highly active, well-tolerated therapy, and providers are now catalyzed to pursue an SM diagnosis in their patients. You can see the graph on the bottom left-hand side of this slide, where we have seen consistent double-digit growth in observable diagnosed SM patients in U.S. claims data over the past few years. We are also seeing that with a strong positive therapeutic experience, healthcare providers are broadening the lens through which they consider who of their SM patients could benefit from AYVAKIT. This tangible growth, combined with new independently published epidemiology data, suggests that the true prevalence of SM is nearly twice the previous estimate and has all added together to add to our evolution of our view of how big this SM market can really be. We've revised our market opportunity projections today. We now estimate our SM franchise to be able to achieve a peak of $4 billion, along with our estimate that AYVAKIT will achieve $2 billion in revenue by 2030. The key takeaway is that SM opportunity is a tremendous opportunity, high medical need, growing in both the number of patients who are impacted by this disease and growing faster than we expected. Importantly, we have a plan to capture the opportunity that is in front of us. Last year, I stood up here and told you that the first few quarters of launch are critical for any new medicine in establishing a strong foundation and trajectory of growth for the future. In 2024, our team hit it out of the park establishing that foundation. This year, we are going to scale our infrastructure to expand our capabilities so that we can further customize our approach to meeting providers' and patient needs. This includes expanding our field teams in a manner that is commensurate with the larger AYVAKIT opportunity we just talked about and consistent with the market dynamics that we have been observing over the last year. We see more patients who are being diagnosed and treated by a range of specialties, including medical dermatology and gastroenterology, and in engaging with those physicians, we've also understood that they are very interested in caring for these patients over the long-term and finding more of these patients. Additional scale will enable us to reach a wider array of potential prescribers and directly impact a greater percentage of the diagnosed population of SM. We will also be increasing our investments in direct-to-consumer initiatives as we look to engage more patients in a long-term relationship with us at Blueprint Medicines. We are, in addition, increasing our investments in our peer-to-peer program for both healthcare providers and patients. We know it is incredibly impactful for both providers and patients to connect with their peers and understand the experience they have had with AYVAKIT when they're considering starting a patient or considering starting therapy. We are, in addition, adding to the mountain of evidence we have already amassed on AYVAKIT's impact on patients. In SM, healthcare providers and patients find longer-term data on the safety and clinical impact of AYVAKIT very meaningful and motivating in the context of a chronic lifelong disease and treatment. We will continue to follow patients in the PIONEER study, giving us the opportunity to publish even longer-term follow-up with that data on AYVAKIT's impact. And last, but certainly not least, we will continue to expand approval and reimbursement in countries outside of the U.S. for both advanced SM and ISM. We are confident that these investments will continue to drive market growth and will sustain AYVAKIT as the durable market leader across the spectrum of advanced and indolent SM for years to come. And we're not stopping there. We also have a plan to innovate in the treatment of SM to continue to drive improved patient outcomes and extend our leadership for decades. AYVAKIT's impressive efficacy and safety make it extremely hard to beat. So we're not going to just replicate the AYVAKIT development path. We are going to forge new ground based on the important insights we have developed through our ongoing experience in the PIONEER study and our evolved understanding of the breadth of impact indolent Systemic Mastocytosis has on patients. We have designed the phase three HARBOR study to go beyond the existing AYVAKIT ISM label with a focus on endpoints that can demonstrate disease modification, such as prospectively measuring the impact of treatment on bone health, anaphylaxis frequency, and markers of chronic inflammation, among other outcome measures. The power of our early and well-planned product lifecycle strategy is that Blueprint will continue to be in the driver's seat of innovation in SM for years to come. We have the assets and the strategy in place to achieve our goal of continually improving patient outcomes while maximizing the longer-term performance of our durable SM franchise. So now turning to our third key growth driver, which is our BLU-808 program. As I said, I am very pleased to, for the first time, be able to show you our top-line data coming out of our phase I H ealthy Volunteer study. So let's get to it. But before we do, maybe just take a moment to focus on the mast cell. I've talked a lot about the mast cell today. We hosted two really, really good scientific seminars diving deeply into our knowledge of mast cell biology and our view on how mast cell biology is impactful across a range of diseases this year and how all of that comes together to define our differentiated approach with BLU-808. So if you've not had a chance to listen to those, they are still available on our website. So I encourage you to do so. But I'll give you the CliffsNote version here, which is that the mast cell is the master regulator of the immune system. And it is increasingly appreciated as a strategically important therapeutic target in drug development. And KIT is the key control switch for these cells. KIT is expressed by mast cells throughout the body, and it controls mast cell proliferation, maturation, and survival. We designed BLU-808 to raise the bar on what a treatment for mast cell-mediated inflammatory diseases can offer, and that is by taking into account the full patient experience, efficacy, tolerability, and the burden associated with administration. On the left-hand side of this slide, you see the summary of the preclinical profile of BLU-808. BLU-808 exceeded all of our target product profile criteria. It is potent on KIT. It is highly selective, and it has drug-like properties that are compatible with once-daily oral administration. On the right, you see the study design of our phase I First-In-Human Healthy Volunteer study that we initiated less than six months ago. Our BLU-808 team has done a tremendous job executing this phase I study in a very short period of time, enabling us to present top-line data today. In this phase I study, we evaluated six doses plus a placebo in the single ascending dose portion of the study and four doses plus a placebo in the multiple ascending dose portion of the study. The multiple ascending dose, or MAD, was designed with the typical two weeks of dosing, looking at PK and PD at day 15, with four additional weeks of safety follow-up. Today, we are going to share data on all 87 subjects enrolled in this phase I study. I want to note that there were two of the 87 subjects who actually did not complete the entire study protocol. One was a placebo subject who violated study site policies and was removed at day 12. One was a subject on the 6 mg dose who was found out to have a medical history of benign ethnic neutropenia and was removed on day eight. Both were removed at the discretion of the study investigator, but we are including all data that was contributed by those patients here in this dataset for completeness. Let's start by looking at the single ascending dose data. The graph on the left shows the pharmacokinetics. You can see that the PK is dose-dependent with a very good half-life, enabling once-a-day dosing. Importantly, it has a good coefficient of variability and no food effect. The graph on the right shows the percentage change in serum tryptase from baseline. You can see that the tryptase levels decreased rapidly with one dose, and the changes are dose-dependent, reaching a 60% decrease at the highest single dose studied. Now turning to the multiple ascending dose portion of the study. Here, we're focusing on pharmacokinetics first, and you can see here, again, very nice dose-dependent PK. Importantly, all doses achieved steady-state exposure with low variability despite the small numbers included in each one of the groups. Importantly, we are seeing a great range of target coverage, with the 1 mg dose achieving greater than IC50 target coverage, the 3 mg dose achieving IC90, and the 6 mg and 12 mg doses going beyond IC90. Our goal with this program was to define a range of doses to work with at various target coverage levels, and we have certainly achieved that in this study. Turning now to the percent change in serum tryptase from baseline, we see very nice dose-dependent decreases achieving meaningful changes across multiple doses. In the table on the right, you can see those percent decreases in tryptase by dose at day 15, with the maximum decrease being 87% at the 12 mg dose. You can also see in the table that a number of patients had their tryptase level decrease below the lower limit of detection of the assay. This occurred at all doses, with 75% of the patients dipping below the lower limit of detection at the 12 mg dose. BLU-808 was also very well tolerated, with no serious adverse events and no discontinuations or dose modifications due to adverse events. All adverse events in the BLU-808 treatment group were grade 1. The one grade 2 AE occurred in a placebo patient. As expected, we see the on-target side effect of hair color change starting at the 6 mg dose level, where the changes were minor and isolated. We also see that the 12 mg dose level, where the hair color change was more noticeable. In many of these patients, the hair color change is actually quite modest. But because it is an expected side effect of wild-type KIT inhibition, we know that the investigator and study subjects are looking for it. There were also no significant changes in laboratory measures, including in liver transaminases. Here, we are showing the mean neutrophil counts over time across all doses in the placebo group. You may notice that the baseline levels in this study population skew lower than some of the other studies you've probably seen recently. This is due to the ethnic background of the subjects at our study site. As I mentioned earlier, one subject was mistakenly enrolled in the site who had a medical history of benign ethnic neutropenia. This subject's data is included here in the six milligram dose up until day eight, when the subject was removed from the study. Despite our subject's lower baseline levels, we see only modest fluctuations in neutrophil counts throughout treatment. Taken together, these data are exactly what we are hoping to see from BLU-808 in the clinic. We are extremely pleased with the clinical profile demonstrating a highly potent inhibition of wild-type KIT, a well-tolerated profile, a wide therapeutic window, rapid, deep, and sustained reductions in tryptase, and importantly, a PK profile that supports low once-daily oral dosing with no food effect. BLU-808's profile enables us to pursue our differentiated approach to development, allowing us to explore the range of doses as well as dose regimens to be able to match the correct balance for any given disease. What we are really excited about is that we now have the optionality to pursue this new treatment across a range of diseases, significantly broadening our impact by addressing the medical needs of thousands of patients who suffer from allergic inflammatory disease. We believe BLU-808's profile and our differentiated approach will unlock that true pipeline in the medicine opportunity that it represents. We see the opportunity for BLU-808 as twofold. First is to command a large share of significant and established markets. And second is to drive further growth by expanding the treated populations in these markets by offering a highly effective, well-tolerated, and very convenient medicine. This year, our plan is to initiate a series of proof-of-concept studies in a range of diseases, including chronic urticaria, allergic asthma, allergic rhinitis, allergic conjunctivitis, as well as mast cell activation syndrome. Also known as MCAS, this is a disease that is particularly interesting to me, given its strategic adjacency and overlap with Indolent Systemic Mastocytosis. MCAS is an indication that can tie together much of what we know about mast cells across our portfolio. We talked at one of our seminars about how our academic collaborators have been generating data that suggests that up to 20% of MCAS patients may actually have a KIT D816V mutation, further reinforcing the notion that the SM population is much larger than we anticipated, given the significant number of patients who have MCAS. The remaining MCAS patients will have overactive mast cells with a wild-type KIT. So in our development program, we will utilize this enhanced screening to discern which of the MCAS patients are best suited to potentially be treated with BLU-808 and which patients may be eligible for one of our KIT D816V inhibitors. So now I want to touch briefly on our Portfolio of Earlier Stage Programs. At Blueprint, we have invested in our Integrated Research Platform to enable us to drive our growth organically. And our discovery team has and will continue to deliver an impressive track record of innovation, having achieved 17 development candidates so far in our company's lifecycle. We begin by focusing on areas of high medical need where we have a clear understanding of the biology and where patients need new treatments. Next, we work to make drugs with transformative potential. We set the bar high for our continued R&D investment. It's not enough to achieve an incremental advantage. We want medicines that are going to change the standard of care. Finally, we prioritize programs where we are able to evaluate the impact on a stepwise basis, where early data can be predictive of future clinical success. This is a key de-risking paradigm for us as we make sure that our R&D dollars are being invested in the most impactful way. Over the last several years, we have invested in building a robust capability and targeted protein degradation, which is highly complementary to our long-standing small molecule inhibitor platform. This platform is producing development candidates more quickly than we anticipated across compelling targets in both Immunology and Inflammation and Oncology Hematology. We look forward to talking to you more about these programs once they progress to a point where they are the next clear value drivers for Blueprint Medicines. This year, we will invest in growth from the most robust position of financial strength we've ever been in as a company. We began 2025 with AYVAKIT already having achieved a $500 million run rate, which we expect to continue to grow. Our disciplined and focused investment strategy continues to be a hallmark of our approach to building value. We anticipate our cash burn will fall substantially in 2024 over the prior year. At the end of Q3, our cash balance was $882 million. Hot off the press today, we are anticipating about $80 million to be added to that cash balance, reflecting our estimated proceeds from our equity stake in IDRx, which, as we just learned, was being acquired by GSK this morning. Next month, on our earnings call, we will provide our Q4 and 2024 year-end results, as well as our AYVAKIT revenue guidance for 2025. Our guidance will highlight expectations for continued strong and steady growth throughout the year. With a proven track record of discovery, development, and now commercial success, and our unique and differentiated established expertise in mast cell biology and disorders, we are focused on making smart investments in 2025 to drive growth and deliver for more patients globally. Here is a snapshot of what to watch for us this year. We're off to a great start. We already have a check mark, having now presented our BLU-808 healthy volunteer data here today. So we invite you to continue to follow our progress. And now we can turn over to the Q&A portion of the session. Great. Thank you. Yeah, we'll come to that. That's OK. So let's start the Q&A session. For those of you who are in the audience, if you have any questions, you can raise your hands. We have a runner on the floor. And if you're joining us virtually, you can also submit questions on the stage. Lots of questions to go through. And I'm going to pick the key ones that I really want to ask. Because in your comments about the SM market, I jotted down a couple of words: bigger, growing faster. You updated peak opportunity for the entire SM franchise to $4 billion. From last year, I recall your AYVAKIT's peak sales was supposed to be $2 billion. So what gave you that confidence to refresh your guidance today? And I mean, not just for the whole franchise, right? There's also the $2 billion peak sales mark for 2030. What are you seeing from your trajectory so far that gives you that kind of confidence to update the number? Yeah, great. Christina, you want to take that? Sure. Thanks for the question. So as Kate said, we have had really an incredible launch with AYVAKIT in SM. We are delivering really significant clinical value to patients. And we've also been delivering really compelling revenue growth with guidance this year that would manifest as more than 130% year-on-year growth. And that is the first sort of piece that gives us a lot of confidence about the trajectory that we're on. This launch has been off to a great start. We're seeing strong and steady growth in patients on therapy. We're seeing patients staying on therapy for extended durations of time. We're seeing many patients really benefiting from the transformative clinical potential of AYVAKIT. And then, of course, we're seeing very favorable signs in the underlying market dynamics as well. This market opportunity is bigger than we thought, as Kate said, and it's growing faster than we thought, which in some ways may not be a surprise. We've seen this dynamic with other compelling rare disease launches, where you really start to appreciate the true magnitude of the disease opportunity once you have effective therapy available to treat patients, and that's exactly what we're seeing here, so we're seeing double-digit growth in diagnosed patients, frankly, outstripping even what our own internal expectations were in terms of what we might see, and that is further bolstered by some of the more recent epidemiology data coming out that suggests that the true prevalence of this disease is much higher than we thought, maybe twice as high as we had thought, and so we expect to continue to see growth in AYVAKIT revenue getting to $2 billion by 2030. And frankly, that's not the end of the story. So we see the potential for significant growth beyond that. And within that $4 billion peak guidance for the entire franchise, how much of it is coming from AYVAKIT? How much of it is coming from elenestinib? Because there's that differentiation that you're trying to push with elenestinib in the trial that you've designed, right? So how are you thinking about that split of $4 billion? The SM opportunity for us is very much anchored by AYVAKIT. And we've talked a lot about the strength that we're seeing there. And I think it's really underscored by that $2 billion by 2030 mile marker that we have put out there. So AYVAKIT is absolutely the anchor. Importantly, the story is not over in 2030. So this opportunity will be far from penetrated in 2030. And in fact, if you think about it, any reasonable sort of estimate of how many patients in the U.S. might be on a treatment when we're at a $2 billion run rate, you would see that it's a minority of even the patients diagnosed today, right? And we're continuing to see really rapid growth in diagnosed patients. So we are very confident as we think about that $2 billion by 2030 milestone. But we also believe there's an opportunity to continue to drive penetration of the SM opportunity well beyond 2030 and have more and more patients being treated. As Kate said, we have the right assets here to really do that, first with AYVAKIT, which I think could grow beyond 2030, certainly, and then with elenestinib, where we're looking to really deliver innovation to patients. And so we have the tools to be able to continue to drive treatment of SM, not just in this decade, but in the next decade and beyond. And so exactly how that plays out will come more into focus, obviously, as we have the HARBOR data and can really make decisions about the optimal way to help as many patients as possible and maximize the value of our franchise, which we think is really important. But again, the important thing is $2 billion by 2030 and a lot of opportunity to continue to grow beyond that. I just want to highlight that I think for a company at our stage of maturation, it's really unique to have such an early and well-planned life cycle strategy around such a tremendous opportunity. And so we're, so as Christy said, just so pleased that we have the assets and we're in the driver's seat to be able to do this. And maybe just switching gear to 808s. I think your data really support what you have set forth initially. I think the key here, as for many, at phase I, you really do want to see the safety. But from what we see with competitors, their programs have been dragged by safety. Liver tox specifically, there's some hypersensitivity issue that just announced last week from another competitor. So I guess one is on your 808. How do you think about dosing as you think about not just the initial POC indication, right? You're trying to go for the larger indication. How do you think about dosing to just kind of maximize on the tunability that you're showing here? And then also secondly is just how do you think about the differentiation from competitors? Just based on what we have seen, right? I think initially I thought the anchor could be on day two, tryptase reduction. So I don't know if you can kind of also give us a sense of just how you think about differentiation as well. Thank you, Brian. I think today is really a great day for the research team and the development team at Blueprint Medicines and for patients probably in the future with type 2 inflammation. Because this is the profile that we were hoping for when our team were designing more than three years ago BLU-808. It's a safe, it's highly potent, it's a very, very low-dose drug, as you can see. And the pharmacology I used to tell all of you, I need to see good pharmacology. This is what we call good pharmacology. And this is what we call a good correlation between the pharmacodynamic marker of reduction of tryptase and the pharmacokinetics of the drug. No food effect, a very good safety profile with a wide therapeutic index or window. You can treat patients in a variety of ways. And I think with this gift that we have today from 808, I think we have the opportunity to really study many options in the POCs. Kate mentioned we are going to four major areas or five major areas of POCs: MCAS, asthma, AR, AC, and obviously chronic urticaria that we think with this profile is fairly direct indication for 808 today. We will share more in the future on how we're thinking about putting on our pants for titrability across this wide range of doses that we have shown. Lastly, I mean, if you look at the slides we put out there, starting from 1 mg, we are already above the IC50 of the inhibition. And you go all the way to 3 mg and 6 mg and 12. I think this is what we have been hoping to see, and we can see it today. OK. And we have about a minute left. So I guess one is capital allocation. That comment is very interesting to me. Just quickly, how do you think about your path to being self-sustainable just coming from AYVAKIT sales? Do you see that near term? And how near term can we see that? Yeah. I mean, what we're most focused on, Brian, is really just the durability of our and our financial strength, and I think where we sit today, we have really compelling opportunities to drive substantial growth of the company by continuing to invest in the AYVAKIT launch, by moving elenestinib forward, and then by now expanding and investing more broadly in BLU-808. This is going to drive a tremendous amount of value for Blueprint Medicines in the near and the long-term. What I'd say is that we expect, as we make those additional investments, we expect our revenue growth to outpace our growth in operating expense, and so that will continue to enable us to be here next year with you, saying that we're continuing to be in a very, very strong financial position. Great. Congrats on the progress, and this concludes the end of our Q&A session. Thank you.